MANKINDPharmaceuticals
Mankind Pharma Ltd — Cash Flow Statement
₹2005.80
+0.73%
Mankind Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.88K Cr | 1.76K Cr | 981.23 Cr | -1.43K Cr | — |
| Repayment Of Debt | -5.07K Cr | -366.74 Cr | -1.79K Cr | -653.94 Cr | — |
| Issuance Of Debt | 12.45K Cr | 400.70 Cr | 1.10K Cr | 1.28K Cr | — |
| Issuance Of Capital Stock | 2.96K Cr | 0.00 | — | — | — |
| Capital Expenditure | -530.76 Cr | -389.21 Cr | -832.07 Cr | -2.35K Cr | — |
| End Cash Position | 403.88 Cr | 382.01 Cr | 304.82 Cr | 283.06 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 66.97 Cr | — | — | — | — |
| Beginning Cash Position | 382.01 Cr | 304.82 Cr | 283.06 Cr | 127.33 Cr | — |
| Effect Of Exchange Rate Changes | 1.31 Cr | 1.17 Cr | 2.32 Cr | 0.48 Cr | — |
| Changes In Cash | -46.41 Cr | 76.02 Cr | 19.44 Cr | 155.25 Cr | — |
| Other Cash Adjustment Inside Changein Cash | -9.40 Cr | 0.00 | — | — | — |
| Financing Cash Flow | 10.23K Cr | 5.27 Cr | -739.73 Cr | 604.62 Cr | — |
| Interest Paid Cff | -98.13 Cr | -26.17 Cr | -41.93 Cr | -17.79 Cr | — |
| Net Common Stock Issuance | 2.96K Cr | 0.00 | — | — | — |
| Common Stock Issuance | 2.96K Cr | 0.00 | — | — | — |
| Net Issuance Payments Of Debt | 7.38K Cr | 33.96 Cr | -695.24 Cr | 624.25 Cr | — |
| Net Short Term Debt Issuance | 2.08K Cr | 34.80 Cr | -669.42 Cr | 626.98 Cr | — |
| Short Term Debt Payments | -4.48K Cr | -339.81 Cr | -1.76K Cr | -645.35 Cr | — |
| Short Term Debt Issuance | 6.56K Cr | 374.61 Cr | 1.09K Cr | 1.27K Cr | — |
| Net Long Term Debt Issuance | 5.30K Cr | -0.84 Cr | -25.83 Cr | -2.73 Cr | — |
| Long Term Debt Payments | -593.14 Cr | -26.93 Cr | -29.67 Cr | -8.59 Cr | — |
| Long Term Debt Issuance | 5.89K Cr | 26.09 Cr | 3.85 Cr | 5.86 Cr | — |
| Investing Cash Flow | -12.68K Cr | -2.08K Cr | -1.05K Cr | -1.37K Cr | — |
| Interest Received Cfi | 67.91 Cr | 40.05 Cr | 12.76 Cr | 12.92 Cr | — |
| Net Investment Purchase And Sale | 895.63 Cr | -1.75K Cr | -185.42 Cr | 492.14 Cr | — |
| Sale Of Investment | 6.39K Cr | 544.89 Cr | 712.24 Cr | 1.68K Cr | — |
| Purchase Of Investment | -5.49K Cr | -2.29K Cr | -897.66 Cr | -1.19K Cr | — |
| Net Investment Properties Purchase And Sale | 7.99 Cr | 0.00 | — | 0.00 | 0.00 |
| Sale Of Investment Properties | 7.99 Cr | 0.00 | — | 0.00 | 0.00 |
| Net Business Purchase And Sale | -13.13K Cr | 7.39 Cr | -10.07 Cr | 20.70 Cr | — |
| Sale Of Business | 562.46 Cr | 0.00 | — | 20.75 Cr | 10.27 Cr |
| Purchase Of Business | -13.70K Cr | 0.00 | -3.83 Cr | -0.04 Cr | — |
| Net Intangibles Purchase And Sale | -59.32 Cr | -67.00 Cr | -43.05 Cr | -1.88K Cr | — |
| Purchase Of Intangibles | -59.32 Cr | -67.00 Cr | -43.05 Cr | -1.88K Cr | — |
| Net PPE Purchase And Sale | -459.46 Cr | -314.70 Cr | -782.97 Cr | -461.72 Cr | — |
| Sale Of PPE | 11.98 Cr | 7.51 Cr | 6.05 Cr | 3.15 Cr | — |
| Purchase Of PPE | -471.44 Cr | -322.21 Cr | -789.02 Cr | -464.87 Cr | — |
| Operating Cash Flow | 2.41K Cr | 2.15K Cr | 1.81K Cr | 919.78 Cr | — |
| Taxes Refund Paid | -566.75 Cr | -441.53 Cr | -323.10 Cr | -499.51 Cr | — |
| Change In Working Capital | -146.42 Cr | -17.57 Cr | 166.73 Cr | -586.12 Cr | — |
| Change In Other Current Liabilities | 266.72 Cr | 53.63 Cr | -44.19 Cr | 192.02 Cr | — |
| Change In Other Current Assets | -97.14 Cr | 118.56 Cr | 166.26 Cr | -592.20 Cr | — |
| Change In Payable | -146.04 Cr | 97.46 Cr | -65.02 Cr | 419.82 Cr | — |
| Change In Inventory | -220.70 Cr | -55.00 Cr | 261.78 Cr | -576.70 Cr | — |
| Change In Receivables | -123.55 Cr | -289.91 Cr | -205.31 Cr | -65.95 Cr | — |
| Other Non Cash Items | 272.76 Cr | -83.51 Cr | -9.27 Cr | -27.80 Cr | — |
| Stock Based Compensation | 26.64 Cr | 23.19 Cr | 0.06 Cr | — | — |
| Provisionand Write Offof Assets | 8.61 Cr | 7.96 Cr | 9.15 Cr | 9.65 Cr | — |
| Depreciation And Amortization | 621.22 Cr | 398.25 Cr | 325.92 Cr | 166.62 Cr | — |
| Amortization Cash Flow | 362.29 Cr | 162.38 Cr | 158.83 Cr | 25.22 Cr | — |
| Depreciation | 258.93 Cr | 398.25 Cr | 167.08 Cr | 141.40 Cr | — |
| Gain Loss On Investment Securities | -163.60 Cr | -133.53 Cr | -37.43 Cr | -87.44 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -2.38 Cr | -3.59 Cr | 3.96 Cr | -4.69 Cr | — |
| Gain Loss On Sale Of PPE | 5.37 Cr | -0.48 Cr | -1.66 Cr | 3.74 Cr | — |
| Gain Loss On Sale Of Business | -163.96 Cr | 0.00 | — | — | — |
| Net Income From Continuing Operations | 2.52K Cr | 2.40K Cr | 1.67K Cr | 1.97K Cr | — |
| Net Other Investing Changes | — | -667.59 Cr | -44.97 Cr | 430.19 Cr | -339.76 Cr |
| Dividends Received Cfi | — | 24000.00 | 24000.00 | 10000.00 | 0.42 Cr |
| Common Stock Dividend Paid | — | — | — | 0.00 | 0.00 |
| Net Other Financing Charges | — | — | — | — | -100.06 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mankind Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.